Physician profile
Mark E Song
NPI 1497865281
$11,410.68
in general payments reported to CMS, 2019-2025
13 companies · $79.22 in 2025
The $79.22 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $154 · 2021: $284 · 2022: $90.69 · 2023: $92.15 · 2024: $218 · 2025: $79.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $10,512.97 | 2019-2021 | |
| Abbvie INC. | $238.13 | 2023-2024 | Botox |
| Allergan, INC. | $211.87 | 2019-2022 | |
| Apyx Medical Corporation | $173.91 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $52.24 | 2025 | Jynarque |
| Glaxosmithkline, LLC. | $50.17 | 2022-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $37.77 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $26.98 | 2025 | Tarpeyo |
| Almatica Pharma LLC | $25.14 | 2023 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $21.86 | 2020 | |
| Shield Therapeutics INC | $20.20 | 2023 | Accrufer |
| Ibsa Pharma INC. | $20.17 | 2021 | |
| Pfizer INC. | $19.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.